Literature DB >> 18046276

[Assessment of risk factors for retinal vein occlusions in patients under 60 years of age].

N Salaun1, M-N Delyfer, M-B Rougier, J-F Korobelnik.   

Abstract

PURPOSE: To assess the biologic factors contributing to the risk for cardiovascular and coagulation problems in patients under 60 years of age with retinal vein occlusions (RVOs) in order to determine the advantages of an exhaustive etiologic search. PATIENTS AND
METHOD: Observational and retrospective study on 43 patients under the age of 60, 30 of whom presented central or hemicentral retinal vein occlusions; 13 were affected with branch retinal vein occlusions. All patients received a systematic check-up including blood pressure measurement, blood cholesterol level, carotid Doppler imaging, intraocular pressure measurement and glaucoma history, presence of thrombophilic factors (protein C/S, activated protein C resistance, antiphospholipid antibodies), and presence of disturbed homocysteine metabolism. A systemic medical history was also taken.
RESULTS: The most frequent factors associated with central retinal vein occlusion (CRVO) were hyperhomocysteinemia (33%), arterial hypertension (23%), hypercholesterolemia (20%), open-angle glaucoma or intraocular hypertension (13%), and diabetes (10%). As for branch retinal vein occlusion, the only notable risk factors were arterial hypertension and hypercholesterolemia (46.2% and 38.5%, respectively). DISCUSSION: and conclusion: Our results are consistent with etiologic data of RVO already reported in the literature. They further underline that there is little advantage to an exhaustive etiologic investigation to detect thrombophilia in the absence of a suggestive medical history. Finally, our data suggest the benefit of checking for hyperhomocysteinemia, frequently found in patients with CRVO, and easily correctable with a vitamin supplement.

Entities:  

Mesh:

Year:  2007        PMID: 18046276     DOI: 10.1016/s0181-5512(07)74029-9

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  8 in total

1.  Retinal vein occlusion: pathophysiology and treatment options.

Authors:  Niral Karia
Journal:  Clin Ophthalmol       Date:  2010-07-30

2.  NONICHEMIC CENTRAL RETINAL VEIN OCCLUSION ASSOCIATED WITH HEREDITARY THROMBOPHYLIA.

Authors:  Andreea Dana Fişuş; Doina Suzana Pop; Monica Blanka Rusu; Florina Vultur; Karin Ursula Horvath
Journal:  Rom J Ophthalmol       Date:  2015 Jul-Sep

3.  [Retrospective case analysis of ophthalmological and systemic risk factors in patients with retinal vascular occlusion].

Authors:  C Klatt; K Purtskhvanidze; H Hasselbach; F Treumer; J Hillenkamp; J Roider
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

4.  Presumed bilateral branch retinal vein occlusions secondary to antiepileptic agents.

Authors:  Rumana N Hussain; Somnath Banerjee
Journal:  Clin Ophthalmol       Date:  2011-05-13

5.  Methylenetetrahydrofolate reductase C677T mutation and risk of retinal vein thrombosis.

Authors:  Mohammad Soleiman Soltanpour; Zahra Soheili; Ali Shakerizadeh; Ali Akbar Pourfathollah; Shahram Samiei; Reza Meshkani; Mohammad Shahjahani; Abbas Karimi
Journal:  J Res Med Sci       Date:  2013-06       Impact factor: 1.852

6.  Stimulation of the toll-like receptor 3 promotes metabolic reprogramming in head and neck carcinoma cells.

Authors:  Mathieu Veyrat; Sylvère Durand; Marion Classe; Tanja Matijevic Glavan; Natalie Oker; Nikiforos-Ioannis Kapetanakis; Xiaojun Jiang; Aurore Gelin; Philippe Herman; Odile Casiraghi; David Zagzag; David Enot; Pierre Busson; Benjamin Vérillaud
Journal:  Oncotarget       Date:  2016-12-13

Review 7.  Recent advances in understanding and managing retinal vein occlusions.

Authors:  Daniel D Esmaili; David S Boyer
Journal:  F1000Res       Date:  2018-04-16

8.  Investigation of methylenetetrahydrofolate reductase C677T and factor V Leiden mutation as a genetic marker for retinal vein occlusion.

Authors:  Nitin Nema; Sonam Verma; Ravindra Kumar
Journal:  Taiwan J Ophthalmol       Date:  2018 Apr-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.